Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas

Condition:   T Cell Lymphoma Intervention:   Drug: Brentuximab Vedotin Sponsors:   Siddhartha Ganguly;   Seattle Genetics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

AbstractHigh-grade B cell lymphomas withMYC andBCL2 and/orBCL6 rearrangements ( “double-hit” lymphoma (DHL)/“triple-hit” lymphoma (THL)) are mature B cell neoplasms with highly aggressive clinical behavior and poor response to therapy. Lymphoblastic transformation of mature B cell neoplasms is an uncommon event that is best recognized for follicular lymphoma (FL). To ou r knowledge, only one case of “B lymphoblastic” transformation of de novo DHL has been reported in the literature. Here, we describe another case of such transformation. The patient was a 57-year-old man who presented wit...
Source: Journal of Hematopathology - Category: Pathology Source Type: research
Publication date: Available online 3 June 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Patrick Stelmach, Klaus Wethmar, Christoph Groth, Daniela V. Wenge, Jörn Albring, Jan-Henrik Mikesch, Christoph Schliemann, Christian Reicherts, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Authors: Kallam A, Armitage JO Abstract INTRODUCTION: T cell lymphomas are a heterogeneous group, with varying incidences, geographic patterns, and risk factors. Although until recently approached in a manner similar to B cell lymphomas, the treatment outcomes are poor and this disease is characterized by high relapse rates. The treatment advances in PTCL have been slow compared to B cell lymphomas. The outcomes of patients who progress following stem cell transplantation are worse. AREAS COVERED: This review focuses on the novel targeted agents that are approved and/or are under investigation for patients with...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
AbstractResearch questionHow is ovarian reserve affected by chemotherapy in patients with Hodgkin lymphoma (HL) who undergo fertility preservation (FP)?MethodsA retrospective study was conducted by reviewing medical records of 105 HL patients referred to the FP unit before starting adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy. Ovarian reserve was evaluated before chemotherapy and at the last follow-up using anti-M üllerian hormone (AMH) and antral follicle count (AFC) measurements. The decrease in AMH was compared with that expected from normograms. AMH was compared between patients who unde...
Source: Journal of Assisted Reproduction and Genetics - Category: Reproduction Medicine Source Type: research
Haploidentical hematopoietic stem cell transplantation followed by post ‐transplant cyclophosphamide provides a well‐tolerated and potentially curable treatment for chemorefractory acute‐type adult T‐cell leukemia/lymphoma. AbstractHaploidentical hematopoietic stem cell transplantation followed by post ‐transplant cyclophosphamide provides a well‐tolerated and potentially curable treatment for chemorefractory acute‐type adult T‐cell leukemia/lymphoma.
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research
CONCLUSIONS: The majority (73.3%) of patients who underwent three mobilization attempts were eventually able to collect enough cells to permit autologous transplantation. Extremely low peripheral blood CD34+ count after the first dose of plerixafor and collection yields during the first two attempts were associated with a poor collection yield on the third attempt. The risks and benefits of a third mobilization should be weighed to facilitate judicious use of resources. PMID: 32483875 [PubMed - as supplied by publisher]
Source: Transfusion - Category: Hematology Authors: Tags: Transfusion Source Type: research
Results of KEYNOTE-204 supports pembrolizumab as new standard of care for patients with classical Hodgkin Lymphoma who have relapsed after autologous stem cell transplant or are ineligible for autologous stem cell transplant.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
This study aims to speculate the rationality of ASCT as first-line treatment, through 3 cases and review of the literature. Patient concerns: 3 young-adult patients with FL received ASCT as first-line treatment. Diagnosis: All the 3 patients were no more than 30 years old and the diagnosis of FL was confirmed by histopathological and immunohistochemical evaluations. They all had multi-organ involvements, and two of them presented with a “leukemic-like” manifestation. Compared with those in the previous literatures, the 3 patients were relatively younger and had more invasive clinical features. Interventi...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Opinion statementT cell acute lymphoblastic leukemia (T-ALL) occurs in approximately 25 –30% of adult ALL diagnoses. Historically, B cell ALL (B-ALL) and T-ALL have been treated in the same fashion despite differences in the biology of disease. Outcomes in the adolescent/young adult (AYA) population have improved significantly with the utilization of pediatric-based regimens. In addi tion, there may now be a role for the addition of nelarabine to frontline treatment in the AYA population. In older adults, choices in which regimen to pursue should account for the potential toxicities associated with pediatric-based re...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
Adult T cell leukemia-lymphoma (ATL) is an aggressive malignancy secondary to chronic infection with the human T cell leukemia virus type I (HTLV-I) retrovirus. ATL carries a dismal prognosis. ATL classifies into four subtypes (acute, lymphoma, chronic, and smoldering) which display different clinical features, prognosis and response to therapy, hence requiring different clinical management. Smoldering and chronic subtypes respond well to antiretroviral therapy using the combination of zidovudine (AZT) and interferon-alpha (IFN) with a significant prolongation of survival. Conversely, the watch and wait strategy or chemoth...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
More News: Genetics | Lymphoma | Research | Stem Cell Therapy | Stem Cells | Study | Transplants